The myocardial infarction therapeutics pipeline is expected to increase in future due to rise in prevalence of myocardial infarction. Myocardial infarction is also commonly known as heart attack which is symptomatized by decrease in blood supply to the heart muscle due to coronary artery disease. According to American Heart Association, the mortality rate due to cardiovascular disease is higher than other disease. According to British Heart Foundation, in 2015, around 150,155 deaths, occurred due to cardiovascular disease in the U.K. Some of the drivers for the growth of the myocardial infarction therapeutics pipeline include increasing incidence of coronary artery disease, change in lifestyle, lack of exercise, increase in incidence of blood pressure and obesity. According to World Health Organization (WHO), there has been an increase in incidence of heart disease in smokers as compared to non-smokers.
The myocardial infarction is a state of blockage of flow of oxygen-rich blood to a section of heart muscle, leading to the death of muscle. Myocardial infarction most often occurs in case of coronary artery disease in which a waxy substance, known as plaque gets build up inside the coronary artery, decreasing the oxygen-rich blood supply to the heart. This condition is also known as atherosclerosis due to which area of plaque break open inside a coronary artery, leading to the formation of clot. This clot gets bigger with time and leads to the blockage of coronary artery. The heart failure is a condition in which heart cannot pump enough blood to meet the body need. In various cases, a discomfort occurs in the center or left side of the chest which can last for few minutes which goes away and comes back. The upper body discomfort and shortness of breath also occurs in case of cardiac disorders.
Many companies are conducting clinical trials for the development of myocardial infarction pipeline. Shenzhen Salubris Pharmaceuticals Co., Ltd. Has initiated a therapy of Bivalirudin, a thrombin inhibitor along with an anticoagulant in acute myocardial infarction during emergency primary PCI operation. Bayer, Inc. is developing a compound BAY11425 after acute myocardial infarction in patients having left ventricular dysfunction. BAY11425 is currently in Phase II which is being given as a 6 months’ therapy. CSL Behring is developing a compound CSL112 for the treatment of myocardial infarction in patient who also have moderate renal impairment. Some of the major drugs categories that are being given for the treatment of myocardial infarction include, vasodilators, analgesics, antiplatelet agents, b adrenergic blockers, angiotensin converting enzyme inhibitors, angiotensin receptors antagonist, glycoprotein IIb/IIIa inhibitors etc. The other intermediate treatments that are available include aspirin and oxygen therapy. These are some of the initial treatments that are administered to a patient, prior to the other treatments.
Many institutes, associations and companies are collaborating for the development of therapeutic treatments for myocardial infarction. Eli Lilly and Company collaborated with Centocor, Inc. to conduct clinical trials for efficacy and safety of reteplease and abciximab combination therapy, with abciximab alone administered early or just prior to primary percutaneous coronary intervention.
Some of the key players having a pipeline of myocardial infarction therapeutics include Pfizer Inc., Novartis N.V., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, AstraZeneca, Apotex Inc., Par Pharmaceutical Companies, Inc., Sandoz, Mylan N.V.